Premium
Toxicity associated with epirubicin treatments in a large case series of dogs
Author(s) -
Marrington A. M.,
Killick D. R.,
Grant I. A.,
Blackwood L.
Publication year - 2012
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2011.00281.x
Subject(s) - medicine , lethargy , epirubicin , toxicity , anorexia , vomiting , adverse effect , nausea , neutropenia , gastroenterology , chemotherapy , surgery , anesthesia , cyclophosphamide
Epirubicin is a stereoisomer of doxorubicin that is widely used in human oncology. The purpose of this study was to evaluate the toxicity associated with epirubicin administration in dogs. Three hundred and fifteen treatments were administered to 139 dogs. Patients received between one and seven doses. One hundred and sixteen treatments were associated with toxicity in 81 patients (50 episodes of lethargy, 49 of diarrhoea, 42 of vomiting, 40 of anorexia, 2 hypersensitivity reactions and 2 suspected extravasations). Thirty‐six (11%) adverse events resulted in hospitalization in 33 (24%) patients, of which 15 were neutropenic and 9 pyrexic. Mean duration of hospitalization was 3.4 days and 33 patients recovered uneventfully. Owners of 11 patients declined further treatment after toxicity occurred. After 25 treatments associated with toxicity, dose reductions reduced toxicity. The use of prophylactic anti‐emetics, gastroprotectants and antibiotics did not reduce the frequency of gastrointestinal toxicity.